Evidence map›Paper›PMID 24144475›Full record

ArticleVaccine2013

Recombinant Ehrlichia P29 protein induces a protective immune response in a mouse model of ehrlichiosis.

Nagaraja R Thirumalapura, Patricia A Crocquet-Valdes, Tais B Saito, Sunil Thomas, Jere W McBride, David H Walker

Abstract read
In one paragraph

Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Veterinary sciences · 2024
    Review
  3. Review
  4. Article
  5. RecombinantVeterinary sciences · 2022
    Article
  6. Effect of GP19 Peptide Hyperimmune Antiserum on Activated Macrophage duringAnimals : an open access journal from MDPI · 2021
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nagaraja R ThirumalapuraDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0609, United States; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555-0609, United States; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555-0609, United States; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555-0609, United States. Electronic address: nathirum@utmb.edu.
Patricia A Crocquet-Valdes
Tais B Saito
Sunil Thomas
Jere W McBride
David H Walker
The University of Texas Medical Branch at Galveston · US

Funding

PRODUCTION AND SHARING OF ENRLICHIAL RESEARCH REAGENTSR01AI031431 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 1991 to 2010
$3.7M
EHRLICHIA CHAFFEENSIS SURFACE PROTEINSR21AI031431 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2000 to 2000
$437k
Immunity to Ehrlichial InfectionsK22AI089973 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI THIRUMALAPURA, NAGARAJA RAMAVADHANI · 2012 to 2013
$269k
NIAID NIH HHS 5K22AI089973NIAID NIH HHS AI31431NIAID NIH HHS K22 AI089973NIAID NIH HHS R01 AI031431NIAID NIH HHS R21 AI031431
6 · The paper itself

Abstract

Ehrlichioses are emerging tick-borne bacterial diseases of humans and animals for which no vaccines are available. The diseases are caused by obligately intracellular bacteria belonging to the genus Ehrlichia. Several immunoreactive proteins of ehrlichiae have been identified based on their reactivity with immune sera from human patients and animals. These include the major outer membrane proteins, ankyrin repeat proteins and tandem repeat proteins (TRP). Polyclonal antibodies directed against the tandem repeats (TRs) of Ehrlichia chaffeensis TRP32, TRP47 and TRP120 have been shown to provide protection in mice. In the present study, we evaluated E. muris P29, which is the ortholog of E. chaffeensis TRP47 and E. canis TRP36, as a subunit vaccine in a mouse model of ehrlichiosis. Our study indicated that unlike E. chaffeensis TRP47 and E. canis TRP36, orthologs of E. muris (P29) and E. muris-like agent (EMLA) do not contain tandem repeats. Immunization of mice with recombinant E. muris P29 induced significant protection against a challenge infection. The protection induced by E. muris P29 was associated with induction of strong antibody responses. In contrast to development of P29-specific IgG antibodies following immunization, development of P29-specific IgG antibodies, but not IgM antibodies, was impaired during persistent E. muris infection. Furthermore, our study indicated that CD4+ T cells target P29 during E. muris infection and differentiate into IFN-γ-producing Th1 effector/memory cells. In conclusion, our study indicated that orthologs of E. muris P29 showed considerable variation in the central tandem repeat region among different species, induction of P29-specific IgG antibody response was impaired during persistent E. muris infection, and rP29 induced protective immune responses.

Indexed as

AnimalsAntibodies, BacterialBacterial ProteinsBacterial VaccinesCD4-Positive T-LymphocytesDisease Models, AnimalDNA, BacterialEhrlichiaEhrlichiosisFemaleImmunologic MemoryInterferon-gammaMiceMice, Inbred C57BLMolecular Sequence DataRecombinant ProteinsAntibodies, BacterialBacterial ProteinsBacterial VaccinesDNA, BacterialInterferon-gammaRecombinant ProteinsVaccines, SubunitVaccines, SyntheticAntibodyAntigenEhrlichiaIntracellular bacteriaProtective immunityVaccine

Identifiers

PMID24144475
PMCPMC3893061
OpenAlexW2063913509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.